UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 14, 2021

 

MITESCO, INC.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

 

000-53601

 

87-0496850

(State or other jurisdiction of

incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

601 Carlson Parkway, Suite 1050

Minnetonka, MN 55305

(Address of principal executive offices) (Zip Code)

 

(844) 383-8689

(Registrant's telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

   

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

   

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

   

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

N/A

N/A

N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

 

 

 

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

On March 14, 2021, the Board of Directors appointed Phillip Keller its Chief Financial Officer. In connection with Mr. Keller’s appointment as Chief Financial Officer, Mr. Lawrence Diamond will no longer serve as the Company’s Interim Chief Financial Officer. Mr. Diamond will continue to lead the Company’s growth and development as Chief Executive Officer and as a Director of the Board.

 

Prior to joining Mitesco, Mr. Keller, age 54, was the Chief Financial Officer, Secretary and Treasurer of First Choice Health Care Solutions, Inc. since July 2017, a $50 million integrated care platform of non-physician owned orthopedic and spinal care medical centers. He has also served as a member of the board of directors of CryoPoint, LLC, a leader in biorepository services and cryopreservation since April 2012 and as a member of the board of directors of Your Community Bank from May 2013 through December 2017. From November 2015 through July 2017, he was employed by Solution Management Corp, a specialty advisory firm focused on providing financial and operational consulting, as Managing Director. Additionally, from August 2014 through November 2015 he served as the Chief Financial Officer and Senior Vice President of Finance at RehabCare Inc., a $1.5 billion provider of physical, occupational, and speech-language rehabilitation services to hospitals, skilled nursing facilities and home care settings in 47 states. From September 2011 through June 2013 he was Senior Vice President of Finance at PharMerica, Inc. (NYSE: PMC), a $1.8 billion institutional pharmacy, servicing skilled nursing and assisted living facilities, hospitals, and other long-term alternative care facilities. He also served as the Senior Vice President and Chief Accounting Officer of BioScrip, Inc. (NASDAQ:BIOS), a $1.6 billion specialty pharmaceuticals and homecare company providing comprehensive cost-effective solutions to patients, insurance payers and drug manufacturers, from February 2007 through April 2011. From 2000 through 2007 he served as Vice President of Finance, Chief Financial Officer and Treasurer for DMI Furniture Inc. (NASDAQ: DMIF) a $150 million vertically integrated manufacturer, importer and designer of commercial office and residential furniture sold through mass-market retails, wholesalers, and independent retailers. Mr. Keller received his Bachelor of Science in Accountancy from Loyola University of Chicago and is a Certified Public Accountant and Chartered Global Management Accountant. There are no familial relationships between Mr. Keller and any other officer or director of the Company.

 

In connection with his appointment, the Company entered into an employment agreement with Mr. Keller (the “Employment Agreement”), effective March 17, 2021 (the “Effective Date”), pursuant to which the Company has agreed to pay Mr. Keller a base salary of $250,000, payable in accordance with the Company’s standard payroll procedures. In addition, Mr. Keller will be eligible to receive a bonus target of 25% of his base salary, at the sole discretion of the Compensation Committee of the Board. Mr. Keller’s base compensation shall accrue until such time as the Company has sufficient funding. Additionally, pursuant to the Employment Agreement, Mr. Keller has been awarded options (the “Options”) to purchase up to 1 million shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at an exercise price equal to the closing stock price of our Common Stock on March 17, 2021, pursuant to the Mitesco, Inc. 2021 Omnibus Securities and Incentive Plan. The Options vest pursuant to the following schedule: (a) 250,000 of the Options shall vest upon the 90-day anniversary of the Effective Date, (b) 250,000 of the Options shall vest upon the Company’s completion of a $10 million raise, (c) 250,000 of the Options shall vest on the one-year anniversary of the Effective Date, and (d) 250,000 of the Options shall vest once the Company files an Annual Report on Form 10-K that reports $20 million in gross revenue. Upon a change of control of the Company, any unvested Options shall immediately vest.

 

The Employment Agreement is effective from March 17, 2021 until the earlier of Mr. Keller’s resignation or termination by us under the following circumstances (i) a vote of the majority of our directors; (ii) a violation of the securities laws, or (iii) upon his incapacity or inability to perform all the duties set forth in this Agreement due to mental or physical disability. In the event of termination by us, Mr. Keller will only be entitled to compensation owed through the date of termination and all Options that have not yet vested will be cancelled. The Employment Agreement also contains customary non-disclosure, non-compete and confidentiality provisions.

 

The description of the Employment Agreement does not purport to be complete, and is qualified in its entirety by reference to the Employment Agreement, which is filed as exhibit 10.1 to this Current Report on Form 8-K.

 

 

 

Item 8.01

Other Events.

 

On March 16, 2021, the Company issued a press release announcing its appointment of Mr. Keller as its Chief Financial Officer.

 

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information presented in this Item 8.01 of this Current Report on Form 8-K and Exhibit 99.1 is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise be subject to the liabilities of that section, nor is it incorporated by reference into any filing of the Company, under the Securities Act of 1933, or the Securities Exchange Act of 1934, whether made before or after the date hereof, regardless of any general incorporation language in such filing. 

 

Item 9.01

Financial Statements and Exhibits.

 

Exhibit No.

 

Description

10.1

 

Employment Agreement by and between Phillip Keller, Effective March 17, 2021

99.1

 

Press release dated March 17, 2021

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

MITESCO, INC.

 
       

Date: March 17, 2021

By: 

/s/ Lawrence Diamond

 
   

Lawrence Diamond 

 
   

Chief Executive Officer

 

 

 

Exhibit 10.1

EX_234433IMG001.GIF

 

SENIOR EXECUTIVE EMPLOYMENT AGREEMENT

 

This Agreement is made as of the 14th day of March 2021, between the MITESCO, INC. a publicly traded company incorporated in the State of Delaware (“Employer”), and Phillip Keller, residing at XXXXXXXXXXXXXXXXX (“Employee”).

 

WHEREAS, the Employer, the authorized representative of the Employer, desires to employ Phillip Keller as the Chief Financial Officer of the Employer; and

 

WHEREAS, the parties have reached an agreement as to the terms of said employment as more fully set forth in this Agreement.

 

NOW, THEREFORE, in consideration of the promises and the mutual covenants, terms and conditions as hereinafter set forth, the parties hereby agree as follows:

 

1. Nature of Services and Duties.  

 

a. Effective March 17, 2021, Employee shall serve in the position of Chief Financial Officer of Mitesco Inc.  

 

b. At all times during the term of this Agreement, Employee shall use his/her best efforts and apply his/her skill and experience to the proper performance of his/her duties hereunder and to achieve the goals set forth herein.  Employee shall be directly accountable to and work under the authority and direction of the Chief Executive Officer or any “Designee” the CEO shall direct the Employee to report to, and shall report through such offices as may be directed by the CEO, or their Designee, from time to time.  Employee shall perform such executive, managerial and administrative duties and services as are customary for a Chief Financial Officer and such further executive duties as may be specified from time to time by the Chairman, or their Designee, including without limitation:

 

i. Securities and Exchange Commission (SEC) reporting and compliance

 

ii. Taxation Management

 

iii. Accounting and Audit Management

 

iv. Bookkeeping

 

v. Financing / Capital Raising and Capital Structure Management

 

vi. Banking, Investment, and Treasury Management

 

vii. Rick management and Insurance

 

2. Term.  

 

This Agreement shall be effective from March, 17 2021, (“the Commencement Date”), through employees’ resignation, (“the Termination Date”), unless amended by subsequent written agreement of the parties or terminated as provided herein.  The Employee shall be considered a full-time employee as of the Commencement Date.

 

 

 

 

3. Compensation.  

 

(a) Employee shall be paid an annual base salary of Two Hundred Fifty Thousand ($250,000) Dollars payable in accordance with the Employer’s standard payroll procedures, with a performance and salary review to be conducted annually, at which time the Employee’s salary shall be adjusted in accordance with applicable compensation policies.

 

(b) In addition, Employee shall be eligible to receive a bonus target of 25% of base compensation commencing fiscal year 2021, if approved by the Compensation Committee in its sole discretion.

 

(c) The Employee agrees that their Compensation will accrue from the Commencement Date of this agreement until such time as the Company, as determined by the Board, has sufficient funding.

 

(d) The Employee may receive certain awards of incentive stock options, and those awards are subject to certain vesting, or conditions, including, but not limited to the tenure of the Employee, or achievement of certain objectives, as more further defined in the award notice and the S8 policy and procedures, and generally under the terms as noted below:

 

1.Award of Incentive Stock Options. 

 

Mitesco, Inc. (the “Company”) hereby Awards incentive Stock Options of the Company pursuant to vesting terms.  The Stock Options are awarded by a authorization of the Board of Directors within 30 business days of employment start date and priced in accordance with the S8 plan and the plan policies and procedures.

 

2.Vesting is as follows:

 

a) 250,000 options once the Employee has been with the Employer for 90 days from the effective date of this agreement;

 

b) 250,000 options once the Company completes a capital raise of a least $10,000,000;

 

c) 250,000 options once the Employee has been with the Company for 365 days from the effective date of this agreement;

 

d) 250,000 options once the Employer files a 10K that reports $20,000,000 in Gross Revenue;

 

e) In the event of a change in control of the Company, any remaining unvested shares will immediately vest upon change of control of the Company.

 

3. Restrictions on Transfer.

 

Governed by the Stock Option Plan, S8 as filed with the SEC

 

4. Termination. 

 

Employee’s employment hereunder may be terminated by Employer under the following circumstances:

 

(a) A vote of the majority of the members of the Board of Directors;

 

(b) Upon any violations of the Securities laws;

 

(c) Upon incapacity or inability to perform all the duties set forth in this Agreement due to mental or physical disability;

 

If Employee’s employment is terminated by virtue of any of the events described in paragraph (a), (b), or (c) Employee shall be entitled only to compensation though the date of such termination and any incentive stock options that have not vested shall be cancelled in accordance with the S8 plan.

 

5. Confidentiality and Proprietary Information.

 

Employee acknowledges that he/she will be exposed to confidential information of the Employer, which includes confidential information of Mitesco, Inc., and other operations and activities. Confidential information includes, but is not limited to, data relating to the Employer’s operations, customer information, financial data, computer programs, architectural drawings, marketing plans and information, operating procedures and the like, or any other information of the business affairs of Mitesco.

 

 

 

Employee shall not, directly or indirectly, use, disseminate, disclose, or in any way reveal or use beyond the scope of authority granted by the Employer all or any part of such Confidential Information, which he/she has been or will be exposed to, and shall use such Confidential Information only to the extent specifically authorized by the Employer.

 

Upon termination of this Agreement for any reason whatsoever, Employee shall turn over to the Employer all Confidential Information. Employee acknowledges that the Employer may exercise any and all remedies available to it at law or in equity to enforce this Agreement with respect to non-disclosure of any Confidential Information, which Employee has or will become privy to in the performance of its obligations under this Agreement. The parties acknowledge that this provision shall survive the termination of the Agreement.

 

6. Work Product

 

Any programs, systems, plans, software, hardware, devices, and ideas developed by Employee or anyone in the Employee’s Department during the period of Employee’s employment from the date of original hire shall be the exclusive property of the Employer.

 

7. Covenant Not to Compete.  

 

(a) Employee agrees that during the terms of this Agreement he shall devote his full business time, energy, skill, labor, and attention to the affairs of the Employer and its affiliates or subsidiaries, shall promptly and faithfully do and perform all services pertaining thereto that are or may hereafter be required of him by the Employer, and shall not engage in any activities, directly or indirectly, involving a conflict of interest with the business or relations of the Employer or its affiliates or subsidiaries.

 

(b) Employee recognizes that the business of the Employer and its affiliates or subsidiaries are national and international in scope and that the services to be performed hereunder and the methods employed by the Employer or its affiliates or subsidiaries are such as will place Employee in close business and personal relationship with competing businesses of the Employer or its affiliates or subsidiaries.  Therefore, from and after the date of this Agreement and for one year after expiration of this Agreement or termination of this Agreement, Employee shall not, directly or indirectly, for his own benefit or for, with, or through any other person, company, or competitive company to Employer, within the states of Georgia own, manage consult, or be connected with, as owner, partner, joint venture, director, employee, officer, consultant, or in any other capacity whatsoever, engage in any business which is the same as, similar to or competitive with any business activities of the Employer.  “Business” is defined as any compounding retail pharmacy activity.  Employee acknowledges that the restrictive covenants (the “Restrictive Covenants’) contained in this Section are a condition of his employment and are reasonable and valid in geographical and temporary scope and in all other respects.  If any court determines that any Restrictive Covenants, or any part of the Restrictive Covenants, is invalid or unenforceable, the remainder of the Restrictive Covenants and parts thereof shall not thereby be affected and shall be given full effect, without regard to the invalid portion.  If any court determines that any of the Restrictive Covenants, or any part thereof, is invalid and unenforceable because of geographic or temporal scope of such provision, such court shall have the power to reduce the geographic or temporal scope of such provision, as the case may be, and, in its reduced form, such provision shall then be enforceable.

 

(c) If Employee breaches, or threatens to breach, any of the Restrictive Covenants, the Employer, in addition to and not in lieu of any other rights and remedies it may have at law or in equity, shall have the right to injunctive relief; it being acknowledged and agreed to by Employee that any such breach or threatened breach would cause irreparable and continuing injury to the Employer and that money damages would not provide an adequate remedy to the Employer.

 

 

 

8. Miscellaneous.

 

(a) Employee represents to Employer that there are no restrictions or agreements to which he is a party which would be violated by his execution of this Agreement and his employment hereunder.

 

(b) No amendment or waiver of any provision of this Agreement shall be effective unless in writing signed by both parties.

 

(c) Employee shall have no right to assign, transfer, pledge or otherwise encumber any of the rights, nor to delegate any of the duties created by this Agreement.

 

9. Governing Law.

 

This Agreement is subject to and shall be interpreted in accordance with the laws of the State of Delaware.

 

 

EXECUTED, as of the date first written above.

 

 

 

EMPLOYER

 

Lawrence Diamond

 

 

By: ________________________________

 

Date: ______________________________

 

 

 

EMPLOYEE

 

Phillip Keller

 

 

By: ____________________________

 

Date: ______________________________

 

EX_234433IMG003.GIF

844.383.8689

601 Carlson PKWY, Suite 1050 Minnetonka, MN 55305

www.mitescoinc.com

 

 

 

Exhibit 99.1

 

MITESCO EXPANDS EXECUTIVE TEAM, ADDS PHILIP KELLER AS CHIEF FINANCIAL OFFICER

 

 

MINNEAPOLIS, MN, March 17, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Mitesco, Inc. (OTCQB: MITI) today announced the appointment of Mr. Phillip Keller as its Chief Financial Officer (CFO).

 

“Phillip Keller is an excellent addition to our executive team, with over 30 years experience in finance and accounting, including both private and public companies, and numerous M&A transactions,” noted Larry Diamond, CEO. He continued, “Our plans for expansion and uplisting to a major exchange will be challenging and we believe Phillip brings the relevant healthcare and finance experience to complement the existing team. Further, he has significant international experience which may prove valuable to our longer-term plans.”

 

“I am excited to join the Mitesco Team,” says Keller, “Mitesco and its operating companies, The Good Clinic, LLC, and Acelerar Healthcare Holdings, LTD, should be well-positioned to deliver on their mission of improving healthcare.  With tech-forward, relationship-driven solutions, Larry and the entire Mitesco team are bringing a more personal, you-focused approach to healthcare.  I look forward to working with the team to improve quality, lower cost, and increase convenience for patients around the world.”

 

Most recently Mr. Keller was CFO and Secretary for First Choice Health Care Solutions, Inc., Melbourne FL since Jul 2017, a $50 million integrated care platform of non-physician owned orthopedic and spinal care medical centers of excellence; from November 2015 through July 2017, he was employed by Solution Management Corp as Managing Director. The firm is a specialty advisory firm focused on providing financial and operational consulting. During 2014 and 2015 he was employed as CFO by RehabCare Inc., Louisville, KY a $1.5 billion provider of physical, occupational, and speech-language rehabilitation services to hospitals, skilled nursing facilities, and home care setting in 47 states; from 2011 through 2013 he was Senior VP Finance at PharMerica, Inc., Louisville, KY (NYSE) a $1.8 billion institutional pharmacy servicing skilled nursing and assisted living facilities, hospitals, and other long-term alternative care facilities.

 

Mr. Keller’s compensation will be consistent with others on the executive team, including base salary, potential bonus, and long-term equity participation.

 

Our Operations and Subsidiaries: The Good Clinic, LLC, and Acelerar Healthcare Holdings, LTD.

 

The Good Clinic, LLC is a wholly-owned subsidiary of Mitesco N.A. LLC, the holding company for North American operations. The Good Clinic plans to build out a network of clinics using the latest telehealth technology with the nurse practitioner operating as its primary healthcare provider. It will begin in Minneapolis and plans to expand nationwide. Today, 23 states facilitate nurse practitioners practicing to the full scope of their skills and training. The executive team at The Good Clinic™ includes several of the key executives who brought Minute Clinic (previously known as Quickmedix) to scale, which was acquired by CVS for $170 million in 2006.

 

Acelerar Healthcare Holdings, LTD. is the Company’s wholly-owned, Dublin, Ireland-based entity for its European operations.

 

 

 

 

SAFE HARBOR STATEMENT

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than the statement of historical fact contained in this press release are forward-looking statements. In some case, forward-looking statements can be identified by terminology such as "anticipate," "believe," "can," "continue," "could," "estimate, "expect," "intend," "may," "plan," "potential," "predict," "project," "should," or "will"  or the negative of these terms or other comparable terminology and include statements regarding plans to expand The Good Clinic concept of care to additional locations and uplisting, plans for expansion and up listing, the expected contribution of Mr. Keller, Mitesco and its operating companies, The Good Clinic, LLC, and Acelerar Healthcare Holdings, LTD, being well positioned to deliver on their mission of improving healthcare, and working to improve quality, lower cost, and increase convenience for patients around the world..  These forward-looking statements are based on expectations and assumptions as of the date of the press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, our ability to expand The Good Clinic concept of care to additional locations as planned, the expected contribution of Mr. Keller, our ability to deliver on our mission of improving healthcare for patients around the world, and the other factors discussed in Mitesco, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2019, and subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and the Company undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

 

Contact: Mr. Larry Diamond

844-383-8689 x1
investors@MitescoInc.com